Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial
- PMID:10561302
- DOI: 10.1200/JCO.1999.17.8.2396
Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial
Abstract
Purpose: The optimal timing of surgery after preoperative radiotherapy in rectal cancer is unknown. The aim of this trial was to evaluate the role of the interval between preoperative radiotherapy and surgery.
Patients and methods: Patients with rectal carcinoma accessible to rectal digital examination, staged T2 to T3, NX, M0, were randomized before radiotherapy (39 Gy in 13 fractions) into two groups: in the short interval (SI) group, surgery had to be performed within 2 weeks after completion of radiation therapy, compared with 6 to 8 weeks in the long interval (LI) group. Between 1991 and 1995, 201 patients were enrolled onto the study.
Results: A long interval between preoperative radiotherapy and surgery was associated with a significantly better clinical tumor response (53. 1% in the SI group v 71.7% in the LI group, P =.007) and pathologic downstaging (10.3% in the SI group v 26% in the LI group, P =.005). At a median follow-up of 33 months, there were no differences in morbidity, local relapse, and short-term survival between the two groups. Sphincter-preserving surgery was performed in 76% of cases in the LI group versus 68% in the SI group (P = 0.27).
Conclusion: A long interval between preoperative irradiation and surgery provides increased tumor downstaging with no detrimental effect on toxicity and early clinical results. When sphincter preservation is questionable, a long interval may increase the chance of a successful sphincter-saving surgery.
Similar articles
- Pathologic Response, When Increased by Longer Interval, Is a Marker but Not the Cause of Good Prognosis in Rectal Cancer: 17-year Follow-up of the Lyon R90-01 Randomized Trial.Cotte E, Passot G, Decullier E, Maurice C, Glehen O, François Y, Lorchel F, Chapet O, Gerard JP.Cotte E, et al.Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):544-53. doi: 10.1016/j.ijrobp.2015.10.061. Epub 2015 Nov 4.Int J Radiat Oncol Biol Phys. 2016.PMID:26723110Clinical Trial.
- Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer--treatment results at 5-year follow-up.Pach R, Kulig J, Richter P, Gach T, Szura M, Kowalska T.Pach R, et al.Langenbecks Arch Surg. 2012 Jun;397(5):801-7. doi: 10.1007/s00423-011-0890-8. Epub 2011 Dec 15.Langenbecks Arch Surg. 2012.PMID:22170083Free PMC article.Clinical Trial.
- Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial.Gerard JP, Chapet O, Nemoz C, Hartweig J, Romestaing P, Coquard R, Barbet N, Maingon P, Mahe M, Baulieux J, Partensky C, Papillon M, Glehen O, Crozet B, Grandjean JP, Adeleine P.Gerard JP, et al.J Clin Oncol. 2004 Jun 15;22(12):2404-9. doi: 10.1200/JCO.2004.08.170.J Clin Oncol. 2004.PMID:15197202Clinical Trial.
- The use of radiotherapy for patients with low rectal cancer: an overview of the Lyon experience.Gerard JP.Gerard JP.Aust N Z J Surg. 1994 Jul;64(7):457-63. doi: 10.1111/j.1445-2197.1994.tb02256.x.Aust N Z J Surg. 1994.PMID:8010914Review.
- Evaluation of DOWNSTAGING as leading concept in sphincter-saving surgery for rectal cancer after preoperative radio-chemotherapy (Preop RCT).Gentile M, Bucci L, Cerbone D, D'Antonio D, Guarino V.Gentile M, et al.Ann Ital Chir. 2003 Sep-Oct;74(5):555-8.Ann Ital Chir. 2003.PMID:15139712Review.
Cited by
- Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Verheij FS, Qin LX, Gollub MJ, Wu AJ, Lee M, Patil S, Hezel AF, Marcet JE, Cataldo PA, Polite BN, Herzig DO, Liska D, Oommen S, Friel CM, Ternent CA, Coveler AL, Hunt SR, Garcia-Aguilar J; OPRA Consortium.Thompson HM, et al.JAMA Netw Open. 2024 Jan 2;7(1):e2350903. doi: 10.1001/jamanetworkopen.2023.50903.JAMA Netw Open. 2024.PMID:38194231Free PMC article.Clinical Trial.
- Paradigm-shifting new evidence for treatment of rectal cancer.Fichera A, Allaix ME.Fichera A, et al.J Gastrointest Surg. 2014 Feb;18(2):391-7. doi: 10.1007/s11605-013-2297-z. Epub 2013 Jul 26.J Gastrointest Surg. 2014.PMID:23888373Review.
- Short-course preoperative radiotherapy combined with chemotherapy in resectable locally advanced rectal cancer: local control and quality of life.Ciammella P, Ruggieri MP, Galeandro M, D'Abbiero N, Giunta A, Iotti C.Ciammella P, et al.Radiol Med. 2013 Dec;118(8):1397-411. doi: 10.1007/s11547-013-0939-6. Epub 2013 Jun 25.Radiol Med. 2013.PMID:23801387
- [Restaging PET-CT after radiochemotherapy can spare patients with advanced head and neck cancer from neck dissection provided they are in complete remission].Hermann RM, Christiansen H.Hermann RM, et al.Strahlenther Onkol. 2016 Aug;192(8):589-91. doi: 10.1007/s00066-016-1002-z.Strahlenther Onkol. 2016.PMID:27315088Clinical Trial.German.No abstract available.
- Laparoscopic lateral pelvic lymph node dissection for lower rectal cancer treated with preoperative chemoradiotherapy.Matsuda T, Hasegawa H, Yamashita K, Tanaka T, Yamamoto M, Kanaji S, Oshikiri T, Nakamura T, Sumi Y, Suzuki S, Kakeji Y.Matsuda T, et al.Surg Endosc. 2020 Mar;34(3):1425-1431. doi: 10.1007/s00464-019-07224-9. Epub 2019 Oct 18.Surg Endosc. 2020.PMID:31628619
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources